Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of the American College of Cardiology

• Publication date

  2009-02-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacc.2008.10.033PMID 19195607
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Exenatide

  2009cited by this paper
• Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium.

  2008cited by this paper
• Toll-Like Receptor 4 Mediates Maladaptive Left Ventricular Remodeling and Impairs Cardiac Function After Myocardial Infarction

  2008cited by this paper
• Myocardial reperfusion injury.

  2007cited by this paper
• Cyclooxygenase-2 Inhibition Increases Mortality, Enhances Left Ventricular Remodeling, and Impairs Systolic Function After Myocardial Infarction in the Pig

  2007cited by this paper
• Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction: The CREATEECLA Randomized Controlled Trial

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Glucagon-Like Peptide-1 Limits Myocardial Stunning following Brief Coronary Occlusion and Reperfusion in Conscious Canines

  2005cited by this paper
• Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

  2005cited by this paper
• Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial.

  2005cited by this paper
• Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.

  2005cited by this paper
• Exenatide

  2005cited by this paper
• Glucagon Like Peptide-1 is Protective Against Myocardial Ischemia/Reperfusion Injury when Given Either as a Preconditioning Mimetic or at Reperfusion in an Isolated Rat Heart Model

  2005cited by this paper
• Myocardial Reperfusion Injury

  2004cited by this paper
• Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy

  2004cited by this paper
• Myocardial Protection at a Crossroads: The Need for Translation Into Clinical Therapy

  2004cited by this paper
• Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

  2004cited by this paper
• Prognostic value of admission glucose in non-diabetic patients with myocardial infarction.

  2004cited by this paper
• Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial.

  2003cited by this paper
• Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome.

  2003cited by this paper
• Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium.

  2003cited by this paper
• Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era?

  2002cited by this paper
• Glucagon-Like Peptide-1 Increases cAMP but Fails to Augment Contraction in Adult Rat Cardiac Myocytes

  2001cited by this paper
• Inhibition of caspase-3 improves contractile recovery of stunned myocardium, independent of apoptosis-inhibitory effects.

  2001cited by this paper
• Metabolic modulation of acute myocardial infarction.

  2001cited by this paper
• Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart.

  2000cited by this paper
• Low-Dose Glucose-Insulin-Potassium Is Ineffective in Acute Myocardial Infarction: Results of a Randomized Multicenter Pol-GIK Trial

  1999cited by this paper
• Effects of critical coronary stenosis on global systolic left ventricular function quantified by pressure-volume relations during dobutamine stress in the canine heart.

  1998cited by this paper
• Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group.

  1998cited by this paper
• Metabolic Modulation of Acute Myocardial Infarction The ECLA Glucose-Insulin-Potassium Pilot Trial

  1998cited by this paper
• Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials.

  1997cited by this paper
• Mechanism of activation of protein kinase B by insulin and IGF‐1.

  1996cited by this paper
• Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year.

  1995cited by this paper
• Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequences

  1995cited by this paper
• Does reperfusion injury exist in humans?

  1993cited by this paper
• Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.

  1993cited by this paper
• Glucose, insulin and platelet fatty acids following myocardial infarction: an association with infarct size.

  1987cited by this paper
• Editorial: The End‐systolic Pressure‐Volume Relation of the Ventricle Definition, Modifications and Clinical Use

  1981cited by this paper
• The end-systolic pressure-volume relation of the ventricle: definition, modifications and clinical use.

  1981cited by this paper

• Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases

  2025cites this paper
• Role of GLP-1 receptor agonists in sepsis and their therapeutic potential in sepsis-induced muscle atrophy (Review)

  2025cites this paper
• Exploring factors predicting the effectiveness of oral semaglutide in Japanese individuals with type 2 diabetes switching from dipeptidyl peptidase 4 inhibitors: a pilot study

  2025cites this paper
• GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies

  2025cites this paper
• Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications

  2025cites this paper
• PYGM Protects Against Myocardial Infarction by Enhancing Glycogenolysis and Facilitating Autophagic Flux.

  2025cites this paper
• Anti-inflammatory strategies for patients with atherosclerotic coronary disease

  2025cites this paper
• Incretins and the cardiovascular system: bridging digestion with metabolism.

  2025cites this paper
• Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial

  2025cites this paper
• Syringaldehyde Alleviates Cardiac Hypertrophy Induced by Hyperglycemia in H9c2 Cells Through GLP-1 Receptor Signals

  2025cites this paper
• Incretin-based therapy: a new horizon in diabetes management

  2024cites this paper
• Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review

  2024cites this paper
• Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance

  2024cites this paper
• Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease

  2024cites this paper
• DEVELOPMENT OF THE CARDIOPROTECTIVE DRUGS CLASS BASED ON PATHOPHYSIOLOGY OF MYOCARDIAL INFARCTION: A COMPREHENSIVE REVIEW.

  2024cites this paper
• Polyethylene glycol loxenatide protects diabetic kidneys by inhibiting GRP78/PERK/eIF2α pathway, and improves cardiac injury by suppressing TLR4/NF-κB inflammatory pathway

  2024cites this paper
• Effect of GLP-1 Receptor Agonist on Ischemia Reperfusion Injury in Rats with Metabolic Syndrome

  2024cites this paper
• The Quest for Understanding Diabetic Cardiomyopathy: Can We Preserve Function and Prevent Failure?

  2024cites this paper
• Efficacy of the glucagon-like peptide-1 agonist Exenatide in patients undergoing coronary artery bypass grafting or aortic valve replacement - a randomized double-blind clinical trial

  2024cites this paper
• Glucose-Lowering Drugs with Proven Cardiovascular Benefit Following Acute Coronary Syndrome in Patients with Type 2 Diabetes: Treatment Gaps and Outcomes

  2024cites this paper
• Molecular Pathways in Diabetic Cardiomyopathy and the Role of Anti-hyperglycemic Drugs Beyond Their Glucose Lowering Effect

  2024cites this paper
• Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease

  2024cites this paper
• GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms

  2024cites this paper
• Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction

  2023cites this paper
• Cardioprotective Actions of a Glucagon‐like Peptide‐1 Receptor Agonist on Hearts Donated After Circulatory Death

  2023cites this paper
• Role of GLP-1 receptor agonist in diabetic cardio-renal disorder: Recent updates of clinical and pre-clinical evidence.

  2023cites this paper
• Gut Molecules in Cardiometabolic Diseases: The Mechanisms behind the Story

  2023cites this paper
• Potential Role of GLP-1 Based Therapeutics in Coronary Artery Disease.

  2023cites this paper
• Thalidomide and a Dipeptidyl Peptidase 4 Inhibitor in a Rat Model of Experimental Autoimmune Myocarditis

  2023cites this paper
• Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective

  2023cites this paper
• Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease

  2023cites this paper
• Circulating Soluble EPCR Levels Are Reduced in Patients with Ischemic Peripheral Artery Disease and Associated with Markers of Endothelial and Vascular Function

  2023cites this paper
• Blocking RIPK2 Function Alleviates Myocardial Ischemia/Reperfusion Injury by Regulating the AKT and NF-κB Pathways

  2023cites this paper
• Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action

  2023cites this paper
• Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP

  2023cites this paper
• Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent

  2023cites this paper
• Glukagon benzeri peptit-1'in yağ doku kaynaklı mezenkimal kök hücrelerinin kardiyomiyositlere dönüşmesi üzerindeki etkisi

  2022cites this paper
• Role of caveolin-eNOS platform and mitochondrial ATP-sensitive potassium channel in abrogated cardioprotective effect of ischemic preconditioning in postmenopausal women

  2022cites this paper
• Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning

  2022cites this paper
• Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials

  2022cites this paper
• Drug therapy for obesity in the Russian Federation: pharmacoepidemiological study

  2022cites this paper
• Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities.

  2022cites this paper
• New Therapeutic Options for Type 2 Diabetes Mellitus and Their Impact Against Ischemic Heart Disease

  2022cites this paper
• Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data

  2022cites this paper
• Discrepancy between the Actions of Glucagon-like Peptide-1 Receptor Ligands in the Protection of the Heart against Ischemia Reperfusion Injury

  2022cites this paper
• Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art

  2022cites this paper
• Promising Therapeutic Candidate for Myocardial Ischemia/Reperfusion Injury: What Are the Possible Mechanisms and Roles of Phytochemicals?

  2022cites this paper
• Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension

  2022cites this paper
• CD14 Involvement in Third-degree Skin Burn-induced Myocardial Injury via the MAPK Signaling Pathway

  2021cites this paper
• Role of glucagon-like peptide-1 agonist in patients undergoing percutaneous coronary intervention or coronary artery bypass grafting: A meta-analysis

  2021cites this paper
• HSP90-Mediates Liraglutide Preconditioning-Induced Cardioprotection by Inhibiting C5a and NF-κB

  2021cites this paper
• Myocardial preservation during primary percutaneous intervention: It's time to rethink?

  2021cites this paper
• Electrocardiographic, hemodynamic, and biochemical evidence on the protective effects of exenatide against phosphine-induced cardiotoxicity in rat model

  2021cites this paper
• A fluid-powered refillable origami heart pouch for minimally invasive delivery of cell therapies in rats and pigs.

  2021cites this paper
• Exendin-4 inhibits high glucose-induced oxidative stress in retinal pigment epithelial cells by modulating the expression and activation of p66Shc

  2021cites this paper
• Effects of three types of bariatric interventions on myocardial infarct size and vascular function in rats with type 2 diabetes mellitus.

  2021cites this paper
• Molecular Imaging Using Cardiac PET/CT: Opportunities to Harmonize Diagnosis and Therapy

  2021cites this paper
• Neutral Effects of Combined Treatment With GLP-1R Agonist Exenatide and MR Antagonist Potassium Canrenoate on Cardiac Function in Porcine and Murine Chronic Heart Failure Models

  2021cites this paper
• Efficacy of a glucagon-like peptide-1 agonist and restrictive versus liberal oxygen supply in patients undergoing coronary artery bypass grafting or aortic valve replacement: study protocol for a 2-by-2 factorial designed, randomised clinical trial

  2021cites this paper
• Polymer Conjugation of Docosahexaenoic Acid Potentiates Cardioprotective Therapy in Preclinical Models of Myocardial Ischemia/Reperfusion Injury

  2021cites this paper
• Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients

  2021cites this paper
• Stress-Induced Hyperglycaemia in Non-Diabetic Patients with Acute Coronary Syndrome: From Molecular Mechanisms to New Therapeutic Perspectives

  2021cites this paper
• Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor

  2021cites this paper
• Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI)

  2021cites this paper
• The vicious circle of left ventricular dysfunction and diabetes: from pathophysiology to emerging treatments.

  2020cites this paper
• A novel oral glucagon-like peptide 1 receptor agonist protects against diabetic cardiomyopathy via alleviating cardiac lipotoxicity induced mitochondria dysfunction.

  2020cites this paper
• A review of myocardial ischaemia/reperfusion injury: Pathophysiology, experimental models, biomarkers, genetics and pharmacological treatment

  2020cites this paper
• Myocardial ischaemia–reperfusion injury and cardioprotection in perspective

  2020cites this paper
• Natriuretic peptides as the basis of peptide drug discovery for cardiovascular diseases.

  2020cites this paper
• Exendin-4 Attenuates Remodeling in the Remote Myocardium of Rats After an Acute Myocardial Infarction by Activating β-Arrestin-2, Protein Phosphatase 2A, and Glycogen Synthase Kinase-3 and Inhibiting β-Catenin

  2020cites this paper
• Inhibition of autophagy by geniposide protects against myocardial ischemia/reperfusion injury.

  2020cites this paper
• Exendin-4 Ameliorates Cardiac Remodeling in Experimentally Induced Myocardial Infarction in Rats by Inhibiting PARP1/NF-κB Axis in A SIRT1-Dependent Mechanism

  2020cites this paper
• Exendin‐4 protects the hearts of rats from ischaemia/reperfusion injury by boosting antioxidant levels and inhibition of JNK/p66Shc/NADPH axis

  2020cites this paper
• Exendin-4 Protects Against Myocardial Ischemia-Reperfusion Injury by Upregulation of SIRT1 and SIRT3 and Activation of AMPK

  2020cites this paper
• Exendin‐4 exhibits a tumour suppressor effect in SKOVR‐3 and OVACR‐3 ovarian cancer cells lines by the activation of SIRT1 and inhibition of NF‐κB

  2020cites this paper
• Diabetes Mellitus and Acute Myocardial Infarction: Impact on Short and Long-Term Mortality.

  2020cites this paper
• Revisiting pharmacology of oxidative stress and endothelial dysfunction in cardiovascular disease: Evidence for redox-based therapies.

  2020cites this paper
• Diabetes and its complications: Therapies Available, Anticipated and Aspired.

  2020cites this paper
• Heat shock protein 90 inhibition and multi‐target approach to maximize cardioprotection in ischaemic injury

  2020cites this paper
• Protective effect of exenatide (glucagon-like peptide-1 receptor agonist) on renal ischemia–reperfusion injury in diabetic rats

  2020cites this paper
• Effect of hyperglycaemia and diabetes on acute myocardial ischaemia–reperfusion injury and cardioprotection by ischaemic conditioning protocols

  2020cites this paper
• Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-α.

  2020cites this paper
• Pre- and post-conditioning of the heart: an overview of cardioprotective signaling pathways.

  2020cites this paper
• Discovery of new therapeutic redox targets for cardioprotection against ischemia/reperfusion injury and heart failure.

  2020cites this paper
• Exenatide alleviates adriamycin-induced heart dysfunction in mice: Modulation of oxidative stress, apoptosis and inflammation.

  2019cites this paper
• Cardiac innervation in acute myocardial ischaemia/reperfusion injury and cardioprotection.

  2019cites this paper
• Endocrine Mechanisms in Obesity

  2019cites this paper
• Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study.

  2019cites this paper
• Diabetes and Heart Failure: Pathogenesis and Novel Therapeutic Approaches

  2019cites this paper
• Exendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway

  2019cites this paper
• A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.

  2019cites this paper
• Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.

  2019cites this paper
• Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction

  2019cites this paper
• GLP-1 Relaxes Rat Coronary Arteries by Enhancing ATP-Sensitive Potassium Channel Currents

  2019cites this paper
• Novel findings and therapeutic targets on cardioprotection of ischemia/reperfusion injury in STEMI.

  2019cites this paper
• Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS

  2019cites this paper
• Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.

  2019cites this paper
• Exenatide Reduces Graft Injury in a Rat Transplantation Model Using Kidneys Donated after Cardiac Death.

  2019cites this paper
• Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease

  2019cites this paper
• Gut microbiota regulates cardiac ischemic tolerance and aortic stiffness in obesity.

  2019cites this paper